Trials / Terminated
TerminatedNCT05228015
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Ikena Oncology · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally (PO) as monotherapy in subjects with advanced solid tumors with or without gene alterations in the Hippo pathway for whom there are no further treatment options known to confer clinical benefit. The study consists of two phases, an initial Dose Escalation phase followed by a Dose Expansion phase.
Conditions
- Solid Tumors, Adult
- Solid Tumor
- Malignant Pleural Mesothelioma (MPM)
- Epithelioid Hemangioendothelioma (EHE)
- NF2 Deficient Mesothelioma
- Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes
- NF2 Deficiency
- YAP1 or TAZ Gene Fusions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IK-930 | tablets for oral administration |
| DRUG | Osimertinib | tablets for oral administration |
Timeline
- Start date
- 2022-01-07
- Primary completion
- 2024-08-27
- Completion
- 2024-09-09
- First posted
- 2022-02-08
- Last updated
- 2024-11-18
Locations
12 sites across 3 countries: United States, Australia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05228015. Inclusion in this directory is not an endorsement.